U.K. To Decide On Lipitor Patent Wednesday
If Pfizer’s patent assertion is denied and Ranbaxy is permitted to produce a generic version, Pfizer stands to lose billions of dollars. The U.K. represents about 7% of the global market for Lipitor.
Globally, Lipitor had sales of $10.3 billion last year, by far overshadowing sales of runner-up Zocor,...
To view the full article, register now.